Corcept Therapeutics
$116.23Change from previous close: +1.93%Absolute change: +$2.20
At a glance
- Revenue growth
- +12.79%
- 2025 vs 2024
- Net income growth
- −29.43%
- 2025 vs 2024
- Net margin
- 13.1%
- 2024: 20.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 837 | 841 | 622 | 583 | — |
| Current assets | 485 | 472 | 459 | 499 | — |
| Cash and equivalents | 120 | 128 | 136 | 66.3 | — |
| Short-term investments | 252 | 256 | 233 | 365 | — |
| Receivables | 59.8 | 54.0 | 55.1 | 45.1 | — |
| Inventory | 12.9 | 12.4 | 7.7 | 6.1 | — |
| Net property, plant and equipment | 6.5 | 8.0 | 0.3 | 1.8 | — |
| Long-term investments | 160 | 220 | 57.2 | 4.9 | — |
| Current liabilities | 166 | 141 | 105 | 72.5 | — |
| Accounts payable | 40.4 | 15.4 | 17.4 | 12.0 | — |
| Total debt | 6.1 | 6.9 | 0.2 | 1.1 | — |
| Total liabilities | 189 | 161 | 115 | 81.6 | — |
| Total equity (incl. minority) | 648 | 680 | 507 | 502 | — |
| Retained earnings | 643 | 544 | 403 | 296 | — |